{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:38:21Z","timestamp":1762353501769,"version":"build-2065373602"},"reference-count":107,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.critrevonc.2025.104627","type":"journal-article","created":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T12:41:09Z","timestamp":1738845669000},"page":"104627","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations"],"prefix":"10.1016","volume":"209","author":[{"given":"Carla","family":"Colombo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone","family":"De Leo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilaria","family":"Campisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erica","family":"Palesandro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Turco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Buttigliero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Fugazzola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4977-116X","authenticated-orcid":false,"given":"Marcello","family":"Tucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib1","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1210\/jc.2009-2507","article-title":"Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination","volume":"95","author":"Abdulrahman","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104627_bib2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1080\/14737140.2019.1609355","article-title":"Chronic tyrosine kinase inhibitor (TKI) use in metastatic renal cell carcinoma (MRCC): can this lead to the adverse effect of hypogonadism?","volume":"19","author":"Afshar","year":"2019","journal-title":"Expert Rev. Anticancer Ther."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib3","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.ando.2023.03.014","article-title":"Pituitary and adrenal disorders induced by immune checkpoint inhibitors","volume":"84","author":"Albarel","year":"2023","journal-title":"Ann. D. \u2019Endocrinol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1530\/EJE-14-0845","article-title":"Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-ctla-4 antibody in melanoma","volume":"172","author":"Albarel","year":"2015","journal-title":"Eur. J. Endocrinol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104627_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2020-001079","article-title":"Nivolumab plus Ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III checkMate 214 trial","volume":"5","author":"Albiges","year":"2020","journal-title":"ESMO Open"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2022.101635","article-title":"Endocrine immune-related adverse events: adrenal, parathyroid, diabetes insipidus, and lipoatrophy","volume":"36","author":"Atkinson","year":"2022","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104627_bib7","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s40618-020-01226-4","article-title":"Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study","volume":"43","author":"Bai","year":"2020","journal-title":"J Endocrinol Invest"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104627_bib8","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-24-0101","article-title":"Endocrine immune-related adverse events by immune checkpoint inhibitors and potential predictive markers: a prospective study from a single tertiary center","volume":"31","author":"Barlas","year":"2024","journal-title":"Endocr. Relat. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.3390\/cancers14030593","article-title":"Endocrine toxicities of antineoplastic therapy: the adrenal topic","volume":"14","author":"Barnabei","year":"2022","journal-title":"Cancers"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib10","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104627_bib11","doi-asserted-by":"crossref","first-page":"5786","DOI":"10.3390\/cancers15245786","article-title":"Life-threatening endocrinological immune-related adverse events of immune checkpoint inhibitor therapy","volume":"15","author":"Basek","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104627_bib12","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1056\/NEJMoa051140","article-title":"Altered bone and mineral metabolism in patients receiving imatinib mesylate","volume":"354","author":"Berman","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib13","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1210\/jc.2015-1710","article-title":"Diagnosis and treatment of primary adrenal insufficiency: an endocrine society clinical practice guideline","volume":"101","author":"Bornstein","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104627_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104627_bib15","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1210\/jc.2010-2771","article-title":"Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer","volume":"96","author":"Brassard","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib16","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s40618-020-01480-6","article-title":"Baseline serum TSH levels predict the absence of thyroid dysfunction in cancer patients treated with immunotherapy","volume":"44","author":"Brilli","year":"2021","journal-title":"J. Endocrinol. Investig."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib17","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1093\/annonc\/mdw696","article-title":"Immune checkpoint inhibitors-related orchitis","volume":"28","author":"Brunet-Possenti","year":"2017","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104627_bib18","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.ando.2018.07.011","article-title":"Expert opinion on the metabolic complications of new anticancer therapies: tyrosine kinase inhibitors","volume":"79","author":"Buffier","year":"2018","journal-title":"Ann. D. \u2019Endocrinol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib19","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nrendo.2016.205","article-title":"Cancer immunotherapy \u2014 immune checkpoint blockade and associated endocrinopathies","volume":"13","author":"Byun","year":"2017","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104627_bib20","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.ando.2018.07.005","article-title":"Endocrine side-effects of new anticancer therapies: overall monitoring and conclusions","volume":"79","author":"Castinetti","year":"2018","journal-title":"Ann. D. \u2019Endocrinol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib21","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/ERC-18-0320","article-title":"French endocrine society guidance on endocrine side effects of immunotherapy","volume":"26","author":"Castinetti","year":"2019","journal-title":"Endocr. -Relat. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104627_bib22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1210\/er.2018-00006","article-title":"Endocrine toxicity of cancer immunotherapy targeting immune checkpoints","volume":"40","author":"Chang","year":"2019","journal-title":"Endocr. Rev."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104627_bib23","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.3390\/cancers14112687","article-title":"Clinical presentation of immune-related endocrine adverse events during immune checkpoint inhibitor treatment","volume":"14","author":"Chieng","year":"2022","journal-title":"Cancers"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104627_bib24","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104627_bib25","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa2026982","article-title":"CheckMate 9ER Investigators. Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"384","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib26","doi-asserted-by":"crossref","DOI":"10.1530\/ETJ-23-0246","article-title":"Impact of Systemic treatments for advanced thyroid cancer on the adrenal cortex","volume":"13","author":"Colombo","year":"2022","journal-title":"Eur. Thyroid J."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib27","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1210\/jc.2018-01836","article-title":"Primary adrenal insufficiency during lenvatinib or vandetanib and improvement of fatigue after cortisone acetate therapy","volume":"104","author":"Colombo","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104627_bib28","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17446651.2019.1701434","article-title":"Hypophysitis induced by immune checkpoint inhibitors: a 10-year assessment","volume":"14","author":"Dalmazi","year":"2019","journal-title":"Expert Rev. Endocrinol. Metab."},{"issue":"03","key":"10.1016\/j.critrevonc.2025.104627_bib29","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"De Filette","year":"2019","journal-title":"Horm. Metab. Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib30","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/EJE-19-0291","article-title":"Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review","volume":"181","author":"De Filette","year":"2019","journal-title":"Eur. J. Endocrinol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib31","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ando.2023.03.009","article-title":"Endocrine-related adverse conditions induced by tyrosine kinase inhibitors","volume":"84","author":"De Leo","year":"2023","journal-title":"Ann. D. \u2019Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104627_bib32","series-title":"Critical Reviews in Oncology\/Hematology","article-title":"Therapeutic Sequencing in Advanced Renal Cell Carcinoma: How to Choose Considering Clinical and Biological Factors","author":"Delcuratolo","year":"2023"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.505","article-title":"Immune checkpoint inhibitors-induced endocrinopathies: assessment, management and monitoring in a comprehensive cancer centre","volume":"7","author":"Elshafie","year":"2024","journal-title":"Endocrinol. Diabetes Metab."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104627_bib34","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1002\/cncr.31629","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104627_bib35","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1210\/jc.2014-2306","article-title":"Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma","volume":"99","author":"Faje","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104627_bib36","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1530\/EJE-20-0683","article-title":"Therapy of endocrine disease: endocrine-metabolic effects of treatment with multikinase inhibitors","volume":"184","author":"Fallahi","year":"2021","journal-title":"Eur. J. Endocrinol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104627_bib37","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1210\/jc.2016-2118","article-title":"Hormonal replacement in hypopituitarism in adults: an endocrine society clinical practice guideline","volume":"101","author":"Fleseriu","year":"2016","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104627_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-56026-5","article-title":"Immune check point inhibitors-induced hypophysitis: a retrospective analysis of the french pharmacovigilance database","volume":"9","author":"Garon-Czmil","year":"2019","journal-title":"Sci. Rep."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib39","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1634\/theoncologist.2019-0555","article-title":"Immune checkpoint inhibitor-associated primary adrenal insufficiency: WHO vigibase report analysis","volume":"25","author":"Grouthier","year":"2020","journal-title":"Oncologist"},{"issue":"July","key":"10.1016\/j.critrevonc.2025.104627_bib40","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann. Oncol."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104627_bib41","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104627_bib42","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.ando.2018.07.002","article-title":"Expert opinions on adrenal complications in immunotherapy","volume":"79","author":"Haissaguerre","year":"2018","journal-title":"Ann. D. \u2019Endocrinol."},{"issue":"July","key":"10.1016\/j.critrevonc.2025.104627_bib43","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejca.2018.04.001","article-title":"Immunotherapy-induced addison\u2019s disease: a rare, persistent and potentially lethal side-effect","volume":"97","author":"Hescot","year":"2018","journal-title":"Eur. J. Cancer"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib44","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104627_bib45","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: an ESE clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur. J. Endocrinol."},{"issue":"January","key":"10.1016\/j.critrevonc.2025.104627_bib46","article-title":"Nivolumab induced thyroid dysfunction: unusual clinical presentation and challenging diagnosis","volume":"9","author":"Iadarola","year":"2019","journal-title":"Front. Endocrinol."},{"issue":"January","key":"10.1016\/j.critrevonc.2025.104627_bib47","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ejim.2017.08.019","article-title":"Cancer immunotherapy-induced endocrinopathies: clinical behavior and therapeutic approach","volume":"47","author":"Iglesias","year":"2018","journal-title":"Eur. J. Intern. Med."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib48","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1530\/EJE-08-0648","article-title":"Tyrosine kinase inhibitors and modifications of thyroid function tests: a review","volume":"160","author":"Illouz","year":"2009","journal-title":"Eur. J. Endocrinol."},{"issue":"230","key":"10.1016\/j.critrevonc.2025.104627_bib49","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci. Transl. Med."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104627_bib50","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1089\/thy.2018.0116","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","journal-title":"Thyroid"},{"issue":"March","key":"10.1016\/j.critrevonc.2025.104627_bib51","article-title":"Immune checkpoint inhibitor-induced hypophysitis and patterns of loss of pituitary function","volume":"12","author":"Jessel","year":"2022","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib52","doi-asserted-by":"crossref","first-page":"281","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib53","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/cen.13063","article-title":"Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review","volume":"85","author":"Joshi","year":"2016","journal-title":"Clin. Endocrinol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104627_bib54","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1210\/jc.2011-1172","article-title":"Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression","volume":"96","author":"Kappers","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104627_bib55","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res. Care"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104627_bib56","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1200\/OP.23.00023","article-title":"Endocrine dysfunction from immune checkpoint inhibitors: pearls and pitfalls in evaluation and management","volume":"19","author":"Kotwal","year":"2023","journal-title":"JCO Oncol. Pract."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib57","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1136\/jim-2021-002099","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","journal-title":"J. Invest. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2017.0579","article-title":"Risk factors for new hypothyroidism during tyrosine kinase inhibitor therapy in advanced nonthyroidal cancer patients","volume":"28","author":"Lechner","year":"2018","journal-title":"Thyroid"},{"issue":"December","key":"10.1016\/j.critrevonc.2025.104627_bib59","article-title":"Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors","volume":"81","author":"Lee","year":"2022","journal-title":"Cancer Epidemiol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib60","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-023-00951-z","article-title":"Analysis of anti-angiogenesis-related adverse events associated with vascular endothelial growth factor receptor-tyrosine kinase inhibitors (VEGFR-TKIs) in patients with metastatic renal cell carcinoma","volume":"18","author":"Lee","year":"2023","journal-title":"Target. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104627_bib61","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s40618-021-01508-5","article-title":"Higher baseline TSH levels predict early hypothyroidism during cancer immunotherapy","volume":"44","author":"Luongo","year":"2021","journal-title":"J. Endocrinol. Investig."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104627_bib62","doi-asserted-by":"crossref","first-page":"3531","DOI":"10.1210\/jc.2007-0586","article-title":"A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake","volume":"92","author":"Mannavola","year":"2007","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib63","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1158\/1078-0432.CCR-14-2353","article-title":"Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study","volume":"21","author":"Min","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/S2213-8587(13)70031-7","article-title":"Ipilimumab-induced autoimmune adrenalitis","volume":"1","author":"Min","year":"2013","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104627_bib65","article-title":"Cortisol deficiency in lenvatinib treatment of thyroid cancer: an underestimated common adverse event","volume":"December","author":"Monti","year":"2021","journal-title":"Thyroid"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104627_bib66","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"CLEAR Trial Investigators. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104627_bib67","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S1470-2045(13)70093-7","article-title":"Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial","volume":"14","author":"Motzer","year":"2013","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104627_bib68","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/S1470-2045(22)00290-X","article-title":"Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (checkmate 9er): long-term follow-up results from an open-label, randomised, phase 3 trial","volume":"23","author":"Motzer","year":"2022","journal-title":"Lancet Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104627_bib69","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N Engl J Med"},{"issue":"February","key":"10.1016\/j.critrevonc.2025.104627_bib70","article-title":"Glycaemic abnormalities induced by small molecule tryosine kinase inhibitors: a review","volume":"15","author":"Mugiya","year":"2024","journal-title":"Front. Pharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib71","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1089\/thy.2012.0378","article-title":"Inappropriate elevation of serum thyrotropin levels in patients treated with axitinib","volume":"23","author":"Ohba","year":"2013","journal-title":"Thyroid"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib72","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1530\/EC-19-0473","article-title":"Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction","volume":"9","author":"Olsson-Brown","year":"2020","journal-title":"Endocr. Connect."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib73","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002220","article-title":"Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology","volume":"9","author":"\u00d6zdemir","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104627_bib74","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1210\/js.2017-00170","article-title":"Polyendocrinopathy resulting from pembrolizumab in a patient with a malignant melanoma","volume":"1","author":"Paepegaey","year":"2017","journal-title":"J. Endocr. Soc."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104627_bib75","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1089\/thy.2015.0170","article-title":"Thyroid dysfunction in patients with metastatic carcinoma treated with sunitinib: is thyroid autoimmunity involved?","volume":"25","author":"Pani","year":"2015","journal-title":"Thyroid"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104627_bib76","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1177\/0192623308326151","article-title":"Nonclinical safety evaluation of sunitinib: a potent inhibitor of VEGF, PDGF, KIT, FLT3, and RET receptors","volume":"36","author":"Patyna","year":"2008","journal-title":"Toxicol. Pathol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104627_bib77","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.eururo.2023.06.006","article-title":"Pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study","volume":"84","author":"Plimack","year":"2023","journal-title":"Eur. Urol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib78","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104627_bib79","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102994","article-title":"Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trial","volume":"9","author":"Powles","year":"2024","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104627_bib80","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1634\/theoncologist.2018-0722","article-title":"Severe epididymo-orchitis and encephalitis complicating anti-PD-1 therapy","volume":"24","author":"Quach","year":"2019","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2021.100105","article-title":"ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on Axitinib dosing and racial groups","volume":"6","author":"Quinn","year":"2021","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib82","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1007\/s10815-021-02181-6","article-title":"Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review","volume":"38","author":"Rambhatla","year":"2021","journal-title":"J. Assist. Reprod. Genet."},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104627_bib83","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"KEYNOTE-426 Investigators. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104627_bib84","doi-asserted-by":"crossref","first-page":"625","DOI":"10.2217\/fon-2021-0888","article-title":"Risk of toxicity with immunotherapy\u2013tyrosine kinase inhibitors for metastatic renal cell carcinoma: a meta-analysis of randomized controlled trials","volume":"18","author":"Rizzo","year":"2022","journal-title":"Future Oncol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104627_bib85","article-title":"Pembrolizumab-induced thyroiditis, hypophysitis and adrenalitis: a case of triple endocrine dysfunction","volume":"2","author":"Rossi","year":"2024","journal-title":"JCEM Case Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104627_bib86","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1007\/s40618-023-02096-2","article-title":"Predictors of thyroid adverse events during cancer immunotherapy: a real-life experience at a single center","volume":"46","author":"Ruggeri","year":"2023","journal-title":"J. Endocrinol. Investig."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib87","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1530\/ERC-13-0499","article-title":"Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution","volume":"21","author":"Ryder","year":"2014","journal-title":"Endocr. -Relat. Cancer"},{"issue":"36","key":"10.1016\/j.critrevonc.2025.104627_bib88","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib89","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.eprac.2020.09.016","article-title":"Immune checkpoint inhibitor-induced adrenalitis and primary adrenal insufficiency: systematic review and optimal management","volume":"27","author":"Shi","year":"2021","journal-title":"Endocr. Pract."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104627_bib90","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib91","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1530\/EC-17-0257","article-title":"Prednisolone has the same cardiovascular risk profile as hydrocortisone in glucocorticoid replacement","volume":"6","author":"Smith","year":"2017","journal-title":"Endocr. Connect."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104627_bib92","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/cancers15010246","article-title":"Management of endocrine and metabolic toxicities of immune-checkpoint inhibitors: from clinical studies to a real-life scenario","volume":"15","author":"Spagnolo","year":"2022","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib93","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.2337\/dbi18-0002","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib94","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: A Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104627_bib95","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/hepr.13427","article-title":"Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching","volume":"50","author":"Tada","year":"2020","journal-title":"Hepatol. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib96","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1159\/000499089","article-title":"Axitinib-induced hypothyroidism as a predictor of long-term survival in patients with metastatic renal cell carcinoma","volume":"102","author":"Takada","year":"2019","journal-title":"Urol. Int."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104627_bib97","doi-asserted-by":"crossref","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1.2019.\u201d JNCCN","volume":"17","author":"Thompson","year":"2019","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104627_bib98","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"ember","key":"10.1016\/j.critrevonc.2025.104627_bib99","article-title":"Hyponatraemia secondary to nivolumab-induced primary adrenal failure","volume":"2016","author":"Trainer","year":"2016","journal-title":"Endocrinol., Diabetes Metab. Case Rep."},{"issue":"June","key":"10.1016\/j.critrevonc.2025.104627_bib100","article-title":"Review of evidence for adult diabetic ketoacidosis management protocols","volume":"8","author":"Tran","year":"2017","journal-title":"Front. Endocrinol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib101","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2023.0542","article-title":"The combined effect of immune checkpoint inhibitors and tyrosine kinase inhibitors on thyroid function","volume":"34","author":"Tsai","year":"2024","journal-title":"Thyroid"},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104627_bib102","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1007\/s40618-023-02025-3","article-title":"Adrenal insufficiency in thyroid cancer patients treated with tyrosine kinase inhibitors and detected by ACTH stimulation test","volume":"46","author":"Valerio","year":"2023","journal-title":"J. Endocrinol. Investig."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104627_bib103","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/EJE-12-0828","article-title":"Sorafenib therapy decreases the clearance of thyrotropin","volume":"168","author":"Verloop","year":"2013","journal-title":"Eur. J. Endocrinol."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104627_bib104","doi-asserted-by":"crossref","first-page":"1039.e5","DOI":"10.1016\/j.ajem.2017.02.048","article-title":"Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism","volume":"35","author":"Win","year":"2017","journal-title":"Am. J. Emerg. Med."},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104627_bib105","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41574-021-00484-3","article-title":"Endocrine toxicities of immune checkpoint inhibitors","volume":"17","author":"Wright","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.critrevonc.2025.104627_bib106","article-title":"Effects of immune checkpoint inhibitor associated endocrinopathies on cancer survival","volume":"15","author":"Yang","year":"2024","journal-title":"Front Endocrinol. (Lausanne)"},{"issue":"ember","key":"10.1016\/j.critrevonc.2025.104627_bib107","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2147\/EB.S277760","article-title":"\u201c<p>neuro-ophthalmic complications of immune checkpoint inhibitors: a systematic review<\u2009\/P>\u2009.\u201d","volume":"12","author":"Yu","year":"2020","journal-title":"Eye Brain"}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000150?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000150?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:27:03Z","timestamp":1762352823000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":107,"alternative-id":["S1040842825000150"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104627","relation":{},"ISSN":["1040-8428"],"issn-type":[{"type":"print","value":"1040-8428"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Endocrinological toxicities related to immunotherapy combinations for advanced renal cell carcinoma: Practical expert-based management recommendations","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104627","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104627"}}